Bookmark and Share

$CNSP WP1244 Potentially 500X More Potent than Daunorubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work for WP1244 is expected to continue during 2021 and 2022. “WP1244 is a DNA-binding agent believed to be 500-times more potent than daunorubicin in inhibiting tumor cell proliferation,” reads a recent article. “The current target indication for WP1244 includes brain cancers, pancreatic cancers, ovarian cancers and lymphoma. Preclinical studies show high uptake in the brain with antitumor activity.” On the other hand, Berubicin, “a novel anthracycline that is the first anthracycline to cross the blood-brain barrier and is designed to concentrate in tumorous tissue within the brain, is currently entering a potentially pivotal Phase 2 study for GBM.”

To view the full article, visit:

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.

Friday, April 16th, 2021 Uncategorized